Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis.
Banasch
Matthias
M
Goetze
Oliver
O
Schmidt
Wolfgang E
WE
Meier
Juris J
JJ
D052242:Adiponectin / Q000097:blood; D000328:Adult; D001786:Blood Glucose / Q000187:drug effects; D005234:Fatty Liver / Q000178:diet therapy / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008930:Mitochondria, Liver / Q000187:drug effects / Q000378:metabolism; D009765:Obesity / Q000150:complications* / Q000178:diet therapy / Q000188:drug therapy / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000077285:Rimonabant; D012720:Severity of Illness Index; D016896:Treatment Outcome
C499918:ADIPOQ protein, human; D052242:Adiponectin; D001786:Blood Glucose; D007328:Insulin; D008055:Lipids; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant